CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
Levamisole (LEVA) is used to treat worm infections, but it can also inhibit cancer cell growth by inhibiting the aldehyde dehydrogenase pathway. Therefore, here, we developed a drug carrier targeting CD133, a biomarker overexpressed in ovarian cancer cells. The particle structure and cytotoxicity of...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Polymers |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4360/12/2/479 |
id |
doaj-ff95fdd582bd4a9e86087f2c62ee4a8b |
---|---|
record_format |
Article |
spelling |
doaj-ff95fdd582bd4a9e86087f2c62ee4a8b2020-11-25T02:16:10ZengMDPI AGPolymers2073-43602020-02-0112247910.3390/polym12020479polym12020479CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian CancerYu-Chi Wang0Meng-Yi Bai1Ying-Ting Yeh2Sung-Ling Tang3Mu-Hsien Yu4Department of Obstetric and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 10607, TaiwanGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, TaiwanGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, TaiwanDepartment of Pharmacy Practice, Tri-Service General Hospital, Taipei 10607, TaiwanDepartment of Obstetric and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 10607, TaiwanLevamisole (LEVA) is used to treat worm infections, but it can also inhibit cancer cell growth by inhibiting the aldehyde dehydrogenase pathway. Therefore, here, we developed a drug carrier targeting CD133, a biomarker overexpressed in ovarian cancer cells. The particle structure and cytotoxicity of the prepared LEVA-containing particles—called LEVA/PVP/PMMA microparticles (MPs) (because it used matrix material polyvinylpyrrolidone (PVP) and poly(methylmethacrylate) (PMMA))—were investigated in the ovarian cancer cell lines SKOV-3 and CP70. The particle size of the MPs was determined to be 1.0−1.5 µm and to be monodispersed. The hydrophilic property of PVP created a porous MP surface after the MPs were soaked in water for 20 min, which aided the leaching of the hydrophilic LEVA out of the MPs. The encapsulation efficiency of LEVA/PVP/PMMA MPs could reach up to 20%. Free-form LEVA released 50% of drugs in <1 h and 90% of drugs in 1 day, whereas the drug release rate of LEVA/PVP/PMMA MPs was much slower; 50% released in 4 h and only 70% of drugs released in 1 day. In the in vitro cell model test, 5 mM free-form LEVA and 0.1 g/mL CD133 targeted LEVA/PVP/PMMA MPs reduced SKOV-3 cell viability by 60%; 0.1 g/mL LEVA/PVP/PMMA MPs was equivalent to a similar dosage of the free drug. In addition, the cytotoxicity of CD133-conjugated LEVA/PVP/PMMA MPs shows a different cytotoxicity response toward cell lines. For SKOV-3 cells, treatment with free-form LEVA or CD133-conjugated LEVA/PVP/PMMA MPs exerted dose-dependent cytotoxic effects on SKOV-3 cell viability. However, CD133-conjugated LEVA/PVP/PMMA MPs demonstrated no significant dose-dependent cytotoxic efficacy toward CP70 cells.https://www.mdpi.com/2073-4360/12/2/479levamisoledrug carriermicroparticleovarian cancerelectrospray |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yu-Chi Wang Meng-Yi Bai Ying-Ting Yeh Sung-Ling Tang Mu-Hsien Yu |
spellingShingle |
Yu-Chi Wang Meng-Yi Bai Ying-Ting Yeh Sung-Ling Tang Mu-Hsien Yu CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer Polymers levamisole drug carrier microparticle ovarian cancer electrospray |
author_facet |
Yu-Chi Wang Meng-Yi Bai Ying-Ting Yeh Sung-Ling Tang Mu-Hsien Yu |
author_sort |
Yu-Chi Wang |
title |
CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer |
title_short |
CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer |
title_full |
CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer |
title_fullStr |
CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer |
title_full_unstemmed |
CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer |
title_sort |
cd133 targeted pvp/pmma microparticle incorporating levamisole for the treatment of ovarian cancer |
publisher |
MDPI AG |
series |
Polymers |
issn |
2073-4360 |
publishDate |
2020-02-01 |
description |
Levamisole (LEVA) is used to treat worm infections, but it can also inhibit cancer cell growth by inhibiting the aldehyde dehydrogenase pathway. Therefore, here, we developed a drug carrier targeting CD133, a biomarker overexpressed in ovarian cancer cells. The particle structure and cytotoxicity of the prepared LEVA-containing particles—called LEVA/PVP/PMMA microparticles (MPs) (because it used matrix material polyvinylpyrrolidone (PVP) and poly(methylmethacrylate) (PMMA))—were investigated in the ovarian cancer cell lines SKOV-3 and CP70. The particle size of the MPs was determined to be 1.0−1.5 µm and to be monodispersed. The hydrophilic property of PVP created a porous MP surface after the MPs were soaked in water for 20 min, which aided the leaching of the hydrophilic LEVA out of the MPs. The encapsulation efficiency of LEVA/PVP/PMMA MPs could reach up to 20%. Free-form LEVA released 50% of drugs in <1 h and 90% of drugs in 1 day, whereas the drug release rate of LEVA/PVP/PMMA MPs was much slower; 50% released in 4 h and only 70% of drugs released in 1 day. In the in vitro cell model test, 5 mM free-form LEVA and 0.1 g/mL CD133 targeted LEVA/PVP/PMMA MPs reduced SKOV-3 cell viability by 60%; 0.1 g/mL LEVA/PVP/PMMA MPs was equivalent to a similar dosage of the free drug. In addition, the cytotoxicity of CD133-conjugated LEVA/PVP/PMMA MPs shows a different cytotoxicity response toward cell lines. For SKOV-3 cells, treatment with free-form LEVA or CD133-conjugated LEVA/PVP/PMMA MPs exerted dose-dependent cytotoxic effects on SKOV-3 cell viability. However, CD133-conjugated LEVA/PVP/PMMA MPs demonstrated no significant dose-dependent cytotoxic efficacy toward CP70 cells. |
topic |
levamisole drug carrier microparticle ovarian cancer electrospray |
url |
https://www.mdpi.com/2073-4360/12/2/479 |
work_keys_str_mv |
AT yuchiwang cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer AT mengyibai cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer AT yingtingyeh cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer AT sunglingtang cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer AT muhsienyu cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer |
_version_ |
1724892272966762496 |